Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer

被引:0
|
作者
Bidakhvidi, Niloefar Ahmadi [1 ,2 ]
Gevaert, Thomas [3 ]
De Schepper, Maxim [4 ]
Baldewijns, Marcella [4 ]
Havinga, Enrique [5 ]
Deckers, Wies [1 ]
Laenen, Annouschka [6 ]
Devos, Gaetan [3 ,7 ]
Giesen, Alexander [3 ,7 ]
Joniau, Steven [3 ,7 ]
Koole, Michel [1 ,2 ]
Everaerts, Wouter [7 ,8 ]
Deroose, Christophe M. [1 ,2 ]
Goffin, Karolien [1 ,2 ]
机构
[1] Univ Hosp Leuven, Nucl Med, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Imaging & Pathol, Nucl Med & Mol Imaging, Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Dev & Regenerat, Urogenital Abdominal & Plast Surg, Leuven, Belgium
[4] Univ Hosp Leuven, Pathol, Leuven, Belgium
[5] Univ Hosp Leuven, Radiol, Leuven, Belgium
[6] Interuniv Inst Biostat & Stat Bioinformat, Leuven, Belgium
[7] Univ Hosp Leuven, Urol, Leuven, Belgium
[8] Katholieke Univ Leuven, Lab Ion Channel Res, Dept Cellular & Mol Med, Leuven, Belgium
关键词
PSMA PET; PSMA immunohistochemistry; PET/MR; Parametric PET; Primary prostate cancer; IMMUNOREACTIVE SCORE; PET/CT; RECEPTORS; TISSUE; IRS;
D O I
10.1007/s00259-024-06903-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Quantification of PSMA expression via PSMA PET is well-established, however quantification of PSMA via immunohistochemistry (IHC) is not standardized. Our aim was to determine the most optimal PSMA IHC scoring system to quantify PSMA expression with PSMA PET as reference standard. Methods Primary intermediate- and high-risk prostate cancer patients received an [F-18]PSMA-1007 PET/MRI followed by radical prostatectomy. SUVmax, SUVmean and K-i of the prostate tumor was determined. Prostate tumors were stained with anti-PSMA antibodies and scored by 2 readers via 10 IHC scoring systems: histochemical score (H-score), immunoreactivity score(predominant intensity) (IRSpredominant intensity), IRS classification(predominant intensity), IRSmean intensity, IRS classification(mean intensity), Allred score, predominant expression pattern, Shannon diversity index (SDI), percentage negatively stained cells and total percentage positively stained cells. Spearman's rank correlation coefficients (rho) were calculated between PET parameters and IHC scoring systems. Interreader agreement for the IHC scoring systems was measured by the intraclass correlation coefficient (ICC). Results Fifty tumors in 46 patients were analysed. H-score had the best correlation with SUVmax (rho 0.615 p < 0.0001) and SUVmean (rho 0.570, p < 0.0001) and the second best correlation with Ki (rho 0.411, p = 0.0030). SDI had the best correlation with Ki (rho -0.440, p = 0.0014) and the second best correlation with SUVmax (rho -0.516, p = 0.0001) and SUVmean (rho -0.490, p = 0.0003). A moderate interreader agreement was observed for H-score (ICC 0.663, 95% CI 0.495-0.797) and SDI (ICC 0.546, 95% CI 0.354-0.725). Conclusion H-score had the best correlation with PSMA PET quantification and an acceptable interreader agreement. Therefore, we deem H-score the most optimal PSMA IHC scoring system.
引用
收藏
页码:766 / 778
页数:13
相关论文
共 50 条
  • [1] Comparison of PSMA Immunohistochemistry Scoring Systems to Parametric [18F]PSMA-1007 PET/MRI in Primary Prostate Cancer
    Bidakhvidi, N. Ahmadi
    Gevaert, T.
    De Schepper, M.
    Baldewijns, M.
    Havinga, E.
    Deckers, W.
    Laenen, A.
    Devos, G.
    Giesen, A.
    Joniau, S.
    Koole, M.
    Everaerts, W.
    Deroose, C. M.
    Goffin, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S542 - S543
  • [2] [18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
    Loeff, Cato C.
    van Gemert, Willemijn
    Prive, Bastiaan M.
    van Oort, Inge M.
    Hermsen, Rick
    Somford, Diederik M.
    Nagarajah, James
    Heijmen, Linda
    Janssen, Marcel J. R.
    EJNMMI REPORTS, 2024, 8 (01)
  • [3] Molecular Imaging of Prostate Cancer: A direct comparison of the preclinical characteristics of [18F] DCFPyL and [18F]PSMA-1007 and the impact of glutamic acids on [18F]PSMA-1007
    Roscher, M.
    Remde, Y.
    Schaefer, M.
    Bauder-Wuest, U.
    Giesel, F.
    Neels, O. C.
    Cardinale, J.
    Kopka, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S54 - S55
  • [4] Intraindividual Comparison Between [18F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer Patients
    Marinescu, Ioana M.
    Spohn, Simon K. B.
    Kiefer, Selina
    Bronsert, Peter
    Ceci, Lara
    Holzschuh, Julius
    Sigle, August
    Jilg, Cordula A.
    Ruehle, Alexander
    Sprave, Tanja
    Nicolay, Nils H.
    Winzer, Robert
    Rehm, Jana
    Kotzerke, Joerg
    Hoelscher, Tobias
    Grosu, Anca L.
    Ruf, Juri
    Benndorf, Matthias
    Zamboglou, Constantinos
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Role of volumetric parameters on [18F]PSMA-1007 PET/CT in primary staging of prostate cancer
    Castello, A.
    Farulla, L. Airo
    Longari, V.
    Orunesu, E.
    Schiavini, M.
    Bardo, F.
    Arnaboldi, M.
    Galli, E.
    Florimonte, L.
    Castellani, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S488 - S488
  • [6] Comparison of [18F]PSMA-1007 with Novel 18F-Labeled PSMA Inhibitor
    Donat, Cornelius
    Craig, Austin
    Kogler, Juergen
    Laube, Markus
    Kopka, Klaus
    Stadlbauer, Sven
    NUCLEAR MEDICINE AND BIOLOGY, 2023, 126 : S75 - S76
  • [7] Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging
    Chikatamarla, Venkata Avinash
    Okano, Satomi
    Jenvey, Peter
    Ansaldo, Alexander
    Roberts, Matthew J.
    Ramsay, Stuart C.
    Thomas, Paul A.
    Pattison, David A.
    EJNMMI RESEARCH, 2021, 11 (01)
  • [8] Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging
    Venkata Avinash Chikatamarla
    Satomi Okano
    Peter Jenvey
    Alexander Ansaldo
    Matthew J. Roberts
    Stuart C. Ramsay
    Paul A. Thomas
    David A. Pattison
    EJNMMI Research, 11
  • [9] Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
    Clemens Mingels
    Karl Peter Bohn
    Axel Rominger
    Ali Afshar-Oromieh
    Ian Alberts
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 2436 - 2444
  • [10] Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT
    Giesel, Frederik L.
    Will, Leon
    Kesch, Claudia
    Freitag, Martin
    Kremer, Christophe
    Merkle, Jonas
    Neels, Oliver C.
    Cardinale, Jens
    Hadaschik, Boris
    Hohenfellner, Markus
    Kopka, Klaus
    Haberkorn, Uwe
    Kratochwil, Clemens
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (04) : 632 - 635